Sector Update: Health Care Stocks Fall Pre-Bell Thursday
9:19AM ET 5/19/2022 MT NewswiresHealth care stocks fell pre-bell Thursday. The Health Care SPDR (XLV) was 0.66% lower and the iShares NASDAQ Biotechnology Index (IBB) was down 0.54%. SIGA...
Quotes Snapshot > MRSN
Mersana Therapeutics Inc MRSN:NASDAQ
Last Price$3.49NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.04(1.16%)
Bid (Size)$3.49 (259)
Ask (Size)$3.50 (4)
Day Low / High$3.37 - 3.63
Volume1.5 M
Read more news Recent News
Mersana Therapeutics Says FDA has Granted XMT-2056 Orphan Drug Status to Treat Gastric Cancer; Shares Surge Pre-Bell
7:38AM ET 5/19/2022 MT NewswiresMersana Therapeutics (MRSN) said Thursday the US Food and Drug Administration has granted Orphan Drug designation to XMT-2056 to treat gastric cancer. The...
--Baird Adjusts Mersana Therapeutics' Price Target to $18 From $23, Keeps Outperform Rating
9:16AM ET 5/10/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
--Wedbush Adjusts Mersana Therapeutics Price Target to $14 From $18, Maintains Outperform Rating
1:08PM ET 5/09/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q1 2022 Results - Earnings Call Transcript
11:19AM ET 5/09/2022 Seeking AlphaBiotech 101 Lecture 3: Looking At Major Biotech Catalysts
3:23PM ET 3/08/2022 Seeking AlphaMersana Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
12:20PM ET 2/28/2022 Seeking AlphaMersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call Transcript
11:25AM ET 2/28/2022 Seeking AlphaCompany Profile
Business DescriptionMersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 840 Memorial Drive Cambridge, Massachusetts 02139 |
| Phone | +1.617.498.0020 |
| Number of Employees | 86 |
| Recent SEC Filing | 05/18/2022 4 |
| President, Chief Executive Officer & Director | Anna Protopapas |
| Chief Financial Officer & Senior Vice President | Brian DeSchuytner |
| Chief Science & Technology Officer | Timothy B. Lowinger |
| Chief Medical Officer & Senior Vice President | Arvin Yang |
Company Highlights
| Price Open | $3.51 |
| Previous Close | $3.45 |
| 52 Week Range | $2.68 - 15.34 |
| Market Capitalization | $338.5 M |
| Shares Outstanding | 97.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/05/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.49 |
| Beta vs. S&P 500 | N/A |
| Revenue | $10.6 M |
| Net Profit Margin | -8,826.73% |
| Return on Equity | -119.10% |
Analyst Ratings as of 03/18/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |